• News
  • SAN DIEGO
  • BioTech

FDA grants orphan designation to MEI Pharma investigational drug

MEI Pharma Inc. (Nasdaq: MEIP), an oncology company based in San Diego, has been granted an orphan drug designation for the company's investigational drug Pracinostat by the U.S. Food and Drug Administration.

The FDA's Orphan Drug Designation program provides orphan status to drugs defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the country. Pracinostat is being investigated for use in the treatment of acute myeloid leukemia.

The drug is an orally available enzyme inhibitor, targeting histone deacetylase enzymes. It's been tested in a number of Phase 1 and Phase 2 clinical trials, MEI said, in advanced blood disorders and solid tumor indications in both adult and pediatric patients. The company said it has been generally well tolerated in more than 200 patients to date.

Acute myeloid leukemia, also known as acute myelogenous leukemia, is reportedly the most common acute leukemia affecting adults. MEI said its incidence is expected to increase as the population ages. The American Cancer Society estimates about 14,590 new cases of AML per year in the U.S., with an average new patient age of about 66.

The FDA's orphan designation qualifies MEI for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

MEI Pharma Inc.

Company Website

11975 El Camino Real Ste., 101
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
MEIP
1.83
  0.01  
+ 0.55%
335,790,000
8.3
1.47

MEI Pharma Inc. Executive(s):

Daniel Gold

  • Chief Executive Officer, President

Thomas Zech

  • Chief Financial Officer

Related Articles

Subscribe Today!